抗血小板药物对血小板依赖的凝血反应的影响
Ivan A Muravlev1, Anatoly B Dobrovolsky1, Olga A Antonova1
1Chazov National Medical Research Center of Cardiology, Russian Ministry of Health, Academician Chazov Str., 15a, Moscow 121552, Russia.
Biomolecules
|July 29, 2023
概括
抗血小板药物,如蒂卡格洛尔和鲁西罗马布显著降低了血小板驱动的血液凝结和脂素 (PS) 暴露. 单独使用乙撒利酸 (ASA) 没有效果,这表明特定的药物机制抑制了血小板前凝活动.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 活化血小板对于血液凝固至关重要,通过暴露脂素 (PS),加速纤维素形成和血栓生成.
- 了解抗血小板药物如何影响血小板前凝活性对于管理血栓性疾病至关重要.
研究的目的:
- 研究各种抗血小板药物对血小板介导的凝血反应的影响.
- 评估这些药物对血小板暴露脂素 (PS) 的能力的影响.
主要方法:
- 洗净后的人类血小板被化为乙盐酸 (ASA),提卡格勒罗,ASA和提卡格勒罗的组合,鲁西罗玛布或前列腺素E1 (PGE1).
- 血小板激活是由原或内源性血栓激发的. 纤维素形成和血栓生成分别使用再化和化分析进行测量.
- 使用附件V染色和流动细胞计量量化了脂素 (PS) 暴露量.
主要成果:
- 提卡格雷勒 (单独和与ASA),鲁西罗马布和PGE1显著延长了凝血时间,降低了最大凝血速率,并降低了血栓生成峰值和速率.
- 这些药物,但不仅仅是ASA,也减少了PS暴露在激活血小板上.
- 在急性冠状动脉综合征患者中,在提卡格雷勒和ASA治疗中,PS暴露在激活血小板上较低,与没有药物的捐赠者相比.
结论:
- 抗血小板药物ticagrelor,ruciromab和PGE1有效抑制血小板前凝活性和PS暴露.
- 这些发现表明,这些抗血小板药物在体外和体内都抑制了血小板凝固功能.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
Anticoagulant Drugs: Low-Molecular-Weight Heparins
753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Formation of the Platelet Plug
6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Disorders of Hemostasis
992
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
992


